Sudden Cardiac Death clinical trials

Explore recruiting sudden cardiac death clinical trials.

Recruiting sudden cardiac death studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sudden Cardiac Death trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial

Norway, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Sacubitril/valsartan in the prevention of disease progression in patients with an ancient arrhythmogenic service - ARNI-ARVC multicentre randomized trial

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Poland, Spain, Italy, Hungary, France, Germany +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

Germany, Portugal, Netherlands, France, Spain, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2, Open-Label, Dose Finding Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants with Symptomatic BAG3 Mutation-Associated Dilated Cardiomyopathy

Spain, Italy, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with Non-permanent Atrial Fibrillation

Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Sudden Cardiac Death trials by city

Sudden Cardiac Death in Toronto Sudden Cardiac Death in Vancouver Sudden Cardiac Death in Montreal Sudden Cardiac Death in Calgary Sudden Cardiac Death in Edmonton Sudden Cardiac Death in Ottawa Sudden Cardiac Death in Winnipeg Sudden Cardiac Death in Quebec City Sudden Cardiac Death in Hamilton Sudden Cardiac Death in Kitchener Sudden Cardiac Death in London Sudden Cardiac Death in Halifax Sudden Cardiac Death in New York Sudden Cardiac Death in Los Angeles Sudden Cardiac Death in Chicago Sudden Cardiac Death in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease